Home > Products > Featured products

NSC59984

  Cat. No.:  DC9257   Featured
Chemical Structure
803647-40-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 803647-40-7
Chemical Name: NSC-59984,NSC 59984
Synonyms: NSC-59984,NSC 59984
SMILES: CN1CCN(CC1)C(=O)/C=C/C2=CC=C(O2)[N+](=O)[O-]
Formula: C12H15N3O4
M.Wt: 265.27
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
In Vivo: NSC59984 synergizes with CPT11 to induce cell death in mutant p53-expressing colorectal cancer cells and inhibits mutant p53-associated colon tumor xenograft growth in a p73-dependent manner.
In Vitro: NSC59984 specifically restores p53 pathway signaling in mutant p53-expressing human colorectal cancer cells. NSC59984 induces cell death in tumor cells but not normal cells with little or no genotoxicity. NSC59984 induces mutant p53 protein degradation through MDM2-mediated ubiquitination in cancer cells. NSC59984 restores p53 pathway signaling through activation of p73. NSC59984 induces p73-dependent cell apoptosis in cancer.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC10851 PK11000 PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding.
DC9504 YH239-EE YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent
DC7314 Tenovin-3 Tenovin-3 is a small molecule activator of p53 transcriptional activity.
DC8467 RO8994 RO8994 is a potent and selective spiroindolinone MDM2 inhibitor for cancer therapy.
DC8865 RG-7112 RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor.
DC10070 PRIMA-1MET(APR-246) PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity.
DC9902 PRIMA-1 PRIMA-1 is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
DC9257 NSC59984 NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells.
DC10074 MX69 MX69 is the MDM2/XIAP inhibitor, used for cancer treatment.
DC8414 MI-77301 (SAR405838) MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia